Choi et al. [70] showed that BC patients with the basal subtype, characterized by enriched gene expression in the p63 pathway, responded well to neoadjuvant MVAC, while patients with “p53-like tumors,” with activated wild-type p53 gene expression signatures, were resistant to chemotherapy. This evidence concerns the gene TP53 and breast cancer.